Sino Biopharm (1177.HK) Announces 2025 Annual Results
Development Highlights – During the Year, the Group had 4 innovative products approved for marketing by the NMPA, namely, Saitanxin(R) (Culmerciclib Capsules), Hernexeos(R) (Zongertinib Tablets), Putanning(R) (Meloxicam Injection (II)) and Anqixin(R) (Recombinant Human Coagulation Factor VIIa N01 for Injection). – In 2025, the Group’s sales of innovative products reached RMB 15.22 billion, representing a year-on-year […]

















